Researchers Make Strides in Understanding LAG-3 Protein

Researchers at Stanford University and New York University have made significant strides in understanding the properties of the LAG-3 protein, shedding light on its structure and function. This breakthrough could have far-reaching implications for the development of immune checkpoint inhibitor drug candidates targeting LAG-3. The study, published in Proceedings of the National Academy of Sciences, provides crucial insights into the molecular structure of LAG-3 and how it operates. LAG-3, like other checkpoint proteins, serves to prevent the immune system from attacking non-threatening entities. In the context of cancer, these proteins can shield tumor cells from immune recognition, hindering the body’s natural defense mechanisms. While existing antibody treatments focus on checkpoint proteins CTLA-4 and PD-1, the unique mode of action of LAG-3 presents an opportunity for novel approaches in cancer therapy. Scientists are optimistic about the potential of targeting LAG-3, driven by its distinct mechanisms compared to CTLA-4 and PD-1.